

SEQUENCE LISTING

<110> Banerjee, Subhashis
 Taylor, Lori K
 Spiegler, Clive E
 Tracey, Daniel E
 Chartash, Elliot K
 Hoffman, Rebecca S
 Barchuk, William T
 Yan, Philip
 Murtaza, Anwar
 Salfeld, Jochen G
 Fischkoff, Steven

<120> TREATMENT OF METABOLIC DISORDERS
 USING TNF α INHIBITORS

<130> BPI-191

<140>

<141>

<150> 60/397,275

<151> 2002-07-19

<150> 60/411,081

<151> 2002-09-16

<150> 60/417,490

<151> 2002-10-10

<150> 60/455,777

<151> 2003-03-18

<160> 37

<170> FastSEQ for Windows Version 4.0

<210> 1

<211> 107

<212> PRT

<213> Artificial Sequence

<220>

<223> Mutated human antibody

<400> 1

| | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Asp | Ile | Gln | Met | Thr | Gln | Ser | Pro | Ser | Ser | Leu | Ser | Ala | Ser | Val | Gly |
| 1 | | | 5 | | | | | | 10 | | | | | 15 | |
| Asp | Arg | Val | Thr | Ile | Thr | Cys | Arg | Ala | Ser | Gln | Gly | Ile | Arg | Asn | Tyr |
| | | 20 | | | | | 25 | | | | | 30 | | | |
| Leu | Ala | Trp | Tyr | Gln | Gln | Lys | Pro | Gly | Lys | Ala | Pro | Lys | Leu | Leu | Ile |
| | | 35 | | | | | 40 | | | | 45 | | | | |
| Tyr | Ala | Ala | Ser | Thr | Leu | Gln | Ser | Gly | Val | Pro | Ser | Arg | Phe | Ser | Gly |
| | | 50 | | | | 55 | | | | 60 | | | | | |
| Ser | Gly | Ser | Gly | Thr | Asp | Phe | Thr | Leu | Thr | Ile | Ser | Ser | Leu | Gln | Pro |
| 65 | | | | | 70 | | | | 75 | | | | | 80 | |
| Glu | Asp | Val | Ala | Thr | Tyr | Tyr | Cys | Gln | Arg | Tyr | Asn | Arg | Ala | Pro | Tyr |

BPI-191

| | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|--|--|--|--|----|
| | | | | 85 | | | | | | 90 | | | | | 95 |
| Thr | Phe | Gly | Gln | Gly | Thr | Lys | Val | Glu | Ile | Lys | | | | | |
| | | | 100 | | | | | | | 105 | | | | | |

<210> 2
 <211> 121
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Mutated human antibody

<400> 2
 Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Arg
 1 5 10 15
 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Asp Asp Tyr
 20 25 30
 Ala Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
 35 40 45
 Ser Ala Ile Thr Trp Asn Ser Gly His Ile Asp Tyr Ala Asp Ser Val
 50 55 60
 Glu Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr
 65 70 75 80
 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
 85 90 95
 Ala Lys Val Ser Tyr Leu Ser Thr Ala Ser Ser Leu Asp Tyr Trp Gly
 100 105 110
 Gln Gly Thr Leu Val Thr Val Ser Ser
 115 120

<210> 3
 <211> 9
 <212> PRT
 <213> Artificial Sequence

<220>
 <221> VARIANT
 <222> 9
 <223> Xaa = Thr or Ala
 <223> Mutated human antibody

<400> 3
 Gln Arg Tyr Asn Arg Ala Pro Tyr Xaa
 1 5

<210> 4
 <211> 12
 <212> PRT
 <213> Artificial Sequence

<220>
 <221> VARIANT
 <222> 12
 <223> Xaa = Tyr or Asn
 <223> Mutated human antibody

BPI-191

<400> 4

Val Ser Tyr Leu Ser Thr Ala Ser Ser Leu Asp Xaa
1 5 10

<210> 5

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> Mutated human antibody

<400> 5

Ala Ala Ser Thr Leu Gln Ser
1 5

<210> 6

<211> 17

<212> PRT

<213> Artificial Sequence

<220>

<223> Mutated human antibody

<400> 6

Ala Ile Thr Trp Asn Ser Gly His Ile Asp Tyr Ala Asp Ser Val Glu
1 5 10 15
Gly

<210> 7

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> Mutated human antibody

<400> 7

Arg Ala Ser Gln Gly Ile Arg Asn Tyr Leu Ala
1 5 10

<210> 8

<211> 5

<212> PRT

<213> Artificial Sequence

<220>

<223> Mutated human antibody

<400> 8

Asp Tyr Ala Met His
1 5

BPI-191

<210> 9
 <211> 107
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Mutated human antibody

<400> 9
 Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Ile Gly
 1 5 10 15
 Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile Arg Asn Tyr
 20 25 30
 Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile
 35 40 45
 Tyr Ala Ala Ser Thr Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly
 50 55 60
 Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
 65 70 75 80
 Glu Asp Val Ala Thr Tyr Tyr Cys Gln Lys Tyr Asn Ser Ala Pro Tyr
 85 90 95
 Ala Phe Gly Gln Gly Thr Lys Val Glu Ile Lys
 100 105

<210> 10
 <211> 121
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Mutated human antibody

<400> 10
 Gln Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Arg
 1 5 10 15
 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Asp Asp Tyr
 20 25 30
 Ala Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Asp Trp Val
 35 40 45
 Ser Ala Ile Thr Trp Asn Ser Gly His Ile Asp Tyr Ala Asp Ser Val
 50 55 60
 Glu Gly Arg Phe Ala Val Ser Arg Asp Asn Ala Lys Asn Ala Leu Tyr
 65 70 75 80
 Leu Gln Met Asn Ser Leu Arg Pro Glu Asp Thr Ala Val Tyr Tyr Cys
 85 90 95
 Thr Lys Ala Ser Tyr Leu Ser Thr Ser Ser Ser Leu Asp Asn Trp Gly
 100 105 110
 Gln Gly Thr Leu Val Thr Val Ser Ser
 115 120

<210> 11
 <211> 9
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Mutated human antibody

<400> 11

BPI-191

Gln Lys Tyr Asn Ser Ala Pro Tyr Ala
1 5

<210> 12

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<223> Mutated human antibody

<400> 12

Gln Lys Tyr Asn Arg Ala Pro Tyr Ala
1 5

<210> 13

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<223> Mutated human antibody

<400> 13

Gln Lys Tyr Gln Arg Ala Pro Tyr Thr
1 5

<210> 14

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<223> Mutated human antibody

<400> 14

Gln Lys Tyr Ser Ser Ala Pro Tyr Thr
1 5

<210> 15

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<223> Mutated human antibody

<400> 15

Gln Lys Tyr Asn Ser Ala Pro Tyr Thr
1 5

<210> 16

<211> 9

<212> PRT

<213> Artificial Sequence

BPI-191

<220>
<223> Mutated human antibody

<400> 16
Gln Lys Tyr Asn Arg Ala Pro Tyr Thr
1 5

<210> 17
<211> 9
<212> PRT
<213> Artificial Sequence

<220>
<223> Mutated human antibody

<400> 17
Gln Lys Tyr Asn Ser Ala Pro Tyr Tyr
1 5

<210> 18
<211> 9
<212> PRT
<213> Artificial Sequence

<220>
<223> Mutated human antibody

<400> 18
Gln Lys Tyr Asn Ser Ala Pro Tyr Asn
1 5

<210> 19
<211> 9
<212> PRT
<213> Artificial Sequence

<220>
<223> Mutated human antibody

<400> 19
Gln Lys Tyr Thr Ser Ala Pro Tyr Thr
1 5

<210> 20
<211> 9
<212> PRT
<213> Artificial Sequence

<220>
<223> Mutated human antibody

<400> 20
Gln Lys Tyr Asn Arg Ala Pro Tyr Asn
1 5

BPI-191

<210> 21
<211> 9
<212> PRT
<213> Artificial Sequence

<220>
<223> Mutated human antibody

<400> 21
Gln Lys Tyr Asn Ser Ala Ala Tyr Ser
1 5

<210> 22
<211> 9
<212> PRT
<213> Artificial Sequence

<220>
<223> Mutated human antibody

<400> 22
Gln Gln Tyr Asn Ser Ala Pro Asp Thr
1 5

<210> 23
<211> 9
<212> PRT
<213> Artificial Sequence

<220>
<223> Mutated human antibody

<400> 23
Gln Lys Tyr Asn Ser Asp Pro Tyr Thr
1 5

<210> 24
<211> 9
<212> PRT
<213> Artificial Sequence

<220>
<223> Mutated human antibody

<400> 24
Gln Lys Tyr Ile Ser Ala Pro Tyr Thr
1 5

<210> 25
<211> 9
<212> PRT
<213> Artificial Sequence

<220>
<223> Mutated human antibody

BPI-191

<400> 25

Gln Lys Tyr Asn Arg Pro Pro Tyr Thr
1 5

<210> 26

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<223> Mutated human antibody

<400> 26

Gln Arg Tyr Asn Arg Ala Pro Tyr Ala
1 5

<210> 27

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> Mutated human antibody

<400> 27

Ala Ser Tyr Leu Ser Thr Ser Ser Ser Leu Asp Asn
1 5 10

<210> 28

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> Mutated human antibody

<400> 28

Ala Ser Tyr Leu Ser Thr Ser Ser Ser Leu Asp Lys
1 5 10

<210> 29

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> Mutated human antibody

<400> 29

Ala Ser Tyr Leu Ser Thr Ser Ser Ser Leu Asp Tyr
1 5 10

<210> 30

<211> 12

<212> PRT

BPI-191

<213> Artificial Sequence

<220>

<223> Mutated human antibody

<400> 30

Ala Ser Tyr Leu Ser Thr Ser Ser Ser Leu Asp Asp
1 5 10

<210> 31

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> Mutated human antibody

<400> 31

Ala Ser Tyr Leu Ser Thr Ser Phe Ser Leu Asp Tyr
1 5 10

<210> 32

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> Mutated human antibody

<400> 32

Ala Ser Tyr Leu Ser Thr Ser Ser Ser Leu His Tyr
1 5 10

<210> 33

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> Mutated human antibody

<400> 33

Ala Ser Phe Leu Ser Thr Ser Ser Ser Leu Glu Tyr
1 5 10

<210> 34

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> Mutated human antibody

<400> 34

Ala Ser Tyr Leu Ser Thr Ala Ser Ser Leu Glu Tyr
1 5 10

<210> 35
 <211> 12
 <212> PRT
 <213> Artificial Sequence

 <220>
 <223> Mutated human antibody

 <400> 35
 Val Ser Tyr Leu Ser Thr Ala Ser Ser Leu Asp Asn
 1 5 10

<210> 36
 <211> 321
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Mutated human antibody

<400> 36
 gacatccaga tgacccagtc tccatcctcc ctgtctgcat ctgtaggga cagagtcacc 60
 atcacttgtc gggcaagtc gggcatcaga aattacttag cctgggtatca gcaaaaacca 120
 gggaaagccc ctaagctcct gatctatgct gcattccactt tgcaatcagg ggtcccatct 180
 cggttcagtg gcagtggatc tgggacagat ttactctca ccatcagcag cctacagcct 240
 gaagatgttg caacttatta ctgtcaaagg tataaccgtg caccgtatac ttttgccag 300
 gggaccaagg tggaatcaa a 321

<210> 37
 <211> 363
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Mutated human antibody

<400> 37
 gaggtgcagc tgggtggagtc tgggggaggc ttggtacagc ccggcaggtc cctgagactc 60
 tcctgtgcgg cctctggatt cacctttgat gattatgcca tgcaactgggt ccggcaagct 120
 ccagggaagg gcctggaatg ggtctcagct atcacttgga atagtggtca catagactat 180
 gcggactctg tggagggccg attcaccatc tccagagaca acgccaagaa ctccctgtat 240
 ctgcaaatga acagtctgag agctgaggat acggccgtat attactgtgc gaaagtctcg 300
 taccttagca ccgctgctc ccttgactat tggggccaag gtaccctggt caccgtctcg 360
 agt 363